 | • レポートコード：MRC23Q36222 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の核酸マルチプレックスアッセイ市場について調査・分析し、世界の核酸マルチプレックスアッセイ市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（平面核酸アッセイ、ビーズベース核酸アッセイ、その他核酸アッセイ）、用途別セグメント分析（製薬/バイオ企業、病院/研究所、レファレンスラボラトリー、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Luminex Corporation (US)、Thermo Fisher Scientific Inc. (US)、Illumina, Inc (US)、Bio-Rad Laboratories, Inc. (US)、Qiagen N.V. (Netherlands)、Abcam plc (UK)、Becton, Dickinson and Company (US)、Merck KGaA (Germany)、Agilent Technologies, Inc. (US)、Meso Scale Diagnostics (US)、Randox Laboratories (UK)、Quanterix (US)、Bio-Techne Corporation (US)、Olink (Sweden)、DiaSorin S.p.A. (Italy)、Seegene (South Korea)、Promega Corporation (US)、Siemens Healthineers (Germany)、PerkinElmer, Inc. (US)、Shimadzu Biotech (Japan)、Antigenix America, Inc. (US)、Enzo Life Sciences, Inc. (US)、Boster Biological Technology (US)、AYOXXA Biosystems GmbH (Germany)、Cayman Chemical Company (US)などが含まれています。世界の核酸マルチプレックスアッセイ市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、核酸マルチプレックスアッセイ市場規模を推定する際に考慮しました。本レポートは、核酸マルチプレックスアッセイの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、核酸マルチプレックスアッセイに関するビジネス上の意思決定に役立てることを目的としています。 ・核酸マルチプレックスアッセイ市場の概要 - 核酸マルチプレックスアッセイのタイプ別セグメント - 世界の核酸マルチプレックスアッセイ市場規模：タイプ別分析（平面核酸アッセイ、ビーズベース核酸アッセイ、その他核酸アッセイ） - 核酸マルチプレックスアッセイの用途別セグメント - 世界の核酸マルチプレックスアッセイ市場規模：用途別分析（製薬/バイオ企業、病院/研究所、レファレンスラボラトリー、その他） - 世界の核酸マルチプレックスアッセイ市場規模予測（2018年-2029年） ・核酸マルチプレックスアッセイ市場の成長トレンド - 核酸マルチプレックスアッセイの地域別市場規模（2018年-2029年） - 核酸マルチプレックスアッセイ市場ダイナミクス - 核酸マルチプレックスアッセイの業界動向 - 核酸マルチプレックスアッセイ市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：平面核酸アッセイ、ビーズベース核酸アッセイ、その他核酸アッセイ - 世界の核酸マルチプレックスアッセイのタイプ別市場規模（2018年-2023年） - 世界の核酸マルチプレックスアッセイのタイプ別市場規模（2024年-2029年） ・用途別セグメント：製薬/バイオ企業、病院/研究所、レファレンスラボラトリー、その他 - 世界の核酸マルチプレックスアッセイの用途別市場規模（2018年-2023年） - 世界の核酸マルチプレックスアッセイの用途別市場規模（2024年-2029年） ・核酸マルチプレックスアッセイの地域別市場規模 - 北米の核酸マルチプレックスアッセイ市場規模（2018年-2029年） - アメリカの核酸マルチプレックスアッセイ市場規模（2018年-2029年） - ヨーロッパの核酸マルチプレックスアッセイ市場規模（2018年-2029年） - アジア太平洋の核酸マルチプレックスアッセイ市場規模（2018年-2029年） - 中国の核酸マルチプレックスアッセイ市場規模（2018年-2029年） - 日本の核酸マルチプレックスアッセイ市場規模（2018年-2029年） - 韓国の核酸マルチプレックスアッセイ市場規模（2018年-2029年） - インドの核酸マルチプレックスアッセイ市場規模（2018年-2029年） - オーストラリアの核酸マルチプレックスアッセイ市場規模（2018年-2029年） - 中南米の核酸マルチプレックスアッセイ市場規模（2018年-2029年） - 中東・アフリカの核酸マルチプレックスアッセイ市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Luminex Corporation (US)、Thermo Fisher Scientific Inc. (US)、Illumina, Inc (US)、Bio-Rad Laboratories, Inc. (US)、Qiagen N.V. (Netherlands)、Abcam plc (UK)、Becton, Dickinson and Company (US)、Merck KGaA (Germany)、Agilent Technologies, Inc. (US)、Meso Scale Diagnostics (US)、Randox Laboratories (UK)、Quanterix (US)、Bio-Techne Corporation (US)、Olink (Sweden)、DiaSorin S.p.A. (Italy)、Seegene (South Korea)、Promega Corporation (US)、Siemens Healthineers (Germany)、PerkinElmer, Inc. (US)、Shimadzu Biotech (Japan)、Antigenix America, Inc. (US)、Enzo Life Sciences, Inc. (US)、Boster Biological Technology (US)、AYOXXA Biosystems GmbH (Germany)、Cayman Chemical Company (US) ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Nucleic Acid Multiplex Assay market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Nucleic Acid Multiplex Assay is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Nucleic Acid Multiplex Assay is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Nucleic Acid Multiplex Assay in Pharmaceutical & Biotechnology Companies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Nucleic Acid Multiplex Assay include Luminex Corporation (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc (US), Bio-Rad Laboratories, Inc. (US), Qiagen N.V. (Netherlands), Abcam plc (UK), Becton, Dickinson and Company (US), Merck KGaA (Germany) and Agilent Technologies, Inc. (US), etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid Multiplex Assay, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid Multiplex Assay.
The Nucleic Acid Multiplex Assay market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Nucleic Acid Multiplex Assay market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleic Acid Multiplex Assay companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Luminex Corporation (US)
Thermo Fisher Scientific Inc. (US)
Illumina, Inc (US)
Bio-Rad Laboratories, Inc. (US)
Qiagen N.V. (Netherlands)
Abcam plc (UK)
Becton, Dickinson and Company (US)
Merck KGaA (Germany)
Agilent Technologies, Inc. (US)
Meso Scale Diagnostics (US)
Randox Laboratories (UK)
Quanterix (US)
Bio-Techne Corporation (US)
Olink (Sweden)
DiaSorin S.p.A. (Italy)
Seegene (South Korea)
Promega Corporation (US)
Siemens Healthineers (Germany)
PerkinElmer, Inc. (US)
Shimadzu Biotech (Japan)
Antigenix America, Inc. (US)
Enzo Life Sciences, Inc. (US)
Boster Biological Technology (US)
AYOXXA Biosystems GmbH (Germany)
Cayman Chemical Company (US)
Segment by Type
Planar Nucleic Acid Assays
Bead-Based Nucleic Acid Assays
Other Nucleic Acid Assays
Segment by Application
Pharmaceutical & Biotechnology Companies
Hospitals & Research Institutes
Reference Laboratories
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid Multiplex Assay companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid Multiplex Assay Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Planar Nucleic Acid Assays
1.2.3 Bead-Based Nucleic Acid Assays
1.2.4 Other Nucleic Acid Assays
1.3 Market by Application
1.3.1 Global Nucleic Acid Multiplex Assay Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical & Biotechnology Companies
1.3.3 Hospitals & Research Institutes
1.3.4 Reference Laboratories
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid Multiplex Assay Market Perspective (2018-2029)
2.2 Nucleic Acid Multiplex Assay Growth Trends by Region
2.2.1 Global Nucleic Acid Multiplex Assay Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nucleic Acid Multiplex Assay Historic Market Size by Region (2018-2023)
2.2.3 Nucleic Acid Multiplex Assay Forecasted Market Size by Region (2024-2029)
2.3 Nucleic Acid Multiplex Assay Market Dynamics
2.3.1 Nucleic Acid Multiplex Assay Industry Trends
2.3.2 Nucleic Acid Multiplex Assay Market Drivers
2.3.3 Nucleic Acid Multiplex Assay Market Challenges
2.3.4 Nucleic Acid Multiplex Assay Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nucleic Acid Multiplex Assay Players by Revenue
3.1.1 Global Top Nucleic Acid Multiplex Assay Players by Revenue (2018-2023)
3.1.2 Global Nucleic Acid Multiplex Assay Revenue Market Share by Players (2018-2023)
3.2 Global Nucleic Acid Multiplex Assay Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nucleic Acid Multiplex Assay Revenue
3.4 Global Nucleic Acid Multiplex Assay Market Concentration Ratio
3.4.1 Global Nucleic Acid Multiplex Assay Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid Multiplex Assay Revenue in 2022
3.5 Nucleic Acid Multiplex Assay Key Players Head office and Area Served
3.6 Key Players Nucleic Acid Multiplex Assay Product Solution and Service
3.7 Date of Enter into Nucleic Acid Multiplex Assay Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleic Acid Multiplex Assay Breakdown Data by Type
4.1 Global Nucleic Acid Multiplex Assay Historic Market Size by Type (2018-2023)
4.2 Global Nucleic Acid Multiplex Assay Forecasted Market Size by Type (2024-2029)
5 Nucleic Acid Multiplex Assay Breakdown Data by Application
5.1 Global Nucleic Acid Multiplex Assay Historic Market Size by Application (2018-2023)
5.2 Global Nucleic Acid Multiplex Assay Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Nucleic Acid Multiplex Assay Market Size (2018-2029)
6.2 North America Nucleic Acid Multiplex Assay Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nucleic Acid Multiplex Assay Market Size by Country (2018-2023)
6.4 North America Nucleic Acid Multiplex Assay Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nucleic Acid Multiplex Assay Market Size (2018-2029)
7.2 Europe Nucleic Acid Multiplex Assay Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nucleic Acid Multiplex Assay Market Size by Country (2018-2023)
7.4 Europe Nucleic Acid Multiplex Assay Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nucleic Acid Multiplex Assay Market Size (2018-2029)
8.2 Asia-Pacific Nucleic Acid Multiplex Assay Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nucleic Acid Multiplex Assay Market Size by Region (2018-2023)
8.4 Asia-Pacific Nucleic Acid Multiplex Assay Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nucleic Acid Multiplex Assay Market Size (2018-2029)
9.2 Latin America Nucleic Acid Multiplex Assay Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nucleic Acid Multiplex Assay Market Size by Country (2018-2023)
9.4 Latin America Nucleic Acid Multiplex Assay Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nucleic Acid Multiplex Assay Market Size (2018-2029)
10.2 Middle East & Africa Nucleic Acid Multiplex Assay Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nucleic Acid Multiplex Assay Market Size by Country (2018-2023)
10.4 Middle East & Africa Nucleic Acid Multiplex Assay Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Luminex Corporation (US)
11.1.1 Luminex Corporation (US) Company Detail
11.1.2 Luminex Corporation (US) Business Overview
11.1.3 Luminex Corporation (US) Nucleic Acid Multiplex Assay Introduction
11.1.4 Luminex Corporation (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.1.5 Luminex Corporation (US) Recent Development
11.2 Thermo Fisher Scientific Inc. (US)
11.2.1 Thermo Fisher Scientific Inc. (US) Company Detail
11.2.2 Thermo Fisher Scientific Inc. (US) Business Overview
11.2.3 Thermo Fisher Scientific Inc. (US) Nucleic Acid Multiplex Assay Introduction
11.2.4 Thermo Fisher Scientific Inc. (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.2.5 Thermo Fisher Scientific Inc. (US) Recent Development
11.3 Illumina, Inc (US)
11.3.1 Illumina, Inc (US) Company Detail
11.3.2 Illumina, Inc (US) Business Overview
11.3.3 Illumina, Inc (US) Nucleic Acid Multiplex Assay Introduction
11.3.4 Illumina, Inc (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.3.5 Illumina, Inc (US) Recent Development
11.4 Bio-Rad Laboratories, Inc. (US)
11.4.1 Bio-Rad Laboratories, Inc. (US) Company Detail
11.4.2 Bio-Rad Laboratories, Inc. (US) Business Overview
11.4.3 Bio-Rad Laboratories, Inc. (US) Nucleic Acid Multiplex Assay Introduction
11.4.4 Bio-Rad Laboratories, Inc. (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.4.5 Bio-Rad Laboratories, Inc. (US) Recent Development
11.5 Qiagen N.V. (Netherlands)
11.5.1 Qiagen N.V. (Netherlands) Company Detail
11.5.2 Qiagen N.V. (Netherlands) Business Overview
11.5.3 Qiagen N.V. (Netherlands) Nucleic Acid Multiplex Assay Introduction
11.5.4 Qiagen N.V. (Netherlands) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.5.5 Qiagen N.V. (Netherlands) Recent Development
11.6 Abcam plc (UK)
11.6.1 Abcam plc (UK) Company Detail
11.6.2 Abcam plc (UK) Business Overview
11.6.3 Abcam plc (UK) Nucleic Acid Multiplex Assay Introduction
11.6.4 Abcam plc (UK) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.6.5 Abcam plc (UK) Recent Development
11.7 Becton, Dickinson and Company (US)
11.7.1 Becton, Dickinson and Company (US) Company Detail
11.7.2 Becton, Dickinson and Company (US) Business Overview
11.7.3 Becton, Dickinson and Company (US) Nucleic Acid Multiplex Assay Introduction
11.7.4 Becton, Dickinson and Company (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.7.5 Becton, Dickinson and Company (US) Recent Development
11.8 Merck KGaA (Germany)
11.8.1 Merck KGaA (Germany) Company Detail
11.8.2 Merck KGaA (Germany) Business Overview
11.8.3 Merck KGaA (Germany) Nucleic Acid Multiplex Assay Introduction
11.8.4 Merck KGaA (Germany) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.8.5 Merck KGaA (Germany) Recent Development
11.9 Agilent Technologies, Inc. (US)
11.9.1 Agilent Technologies, Inc. (US) Company Detail
11.9.2 Agilent Technologies, Inc. (US) Business Overview
11.9.3 Agilent Technologies, Inc. (US) Nucleic Acid Multiplex Assay Introduction
11.9.4 Agilent Technologies, Inc. (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.9.5 Agilent Technologies, Inc. (US) Recent Development
11.10 Meso Scale Diagnostics (US)
11.10.1 Meso Scale Diagnostics (US) Company Detail
11.10.2 Meso Scale Diagnostics (US) Business Overview
11.10.3 Meso Scale Diagnostics (US) Nucleic Acid Multiplex Assay Introduction
11.10.4 Meso Scale Diagnostics (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.10.5 Meso Scale Diagnostics (US) Recent Development
11.11 Randox Laboratories (UK)
11.11.1 Randox Laboratories (UK) Company Detail
11.11.2 Randox Laboratories (UK) Business Overview
11.11.3 Randox Laboratories (UK) Nucleic Acid Multiplex Assay Introduction
11.11.4 Randox Laboratories (UK) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.11.5 Randox Laboratories (UK) Recent Development
11.12 Quanterix (US)
11.12.1 Quanterix (US) Company Detail
11.12.2 Quanterix (US) Business Overview
11.12.3 Quanterix (US) Nucleic Acid Multiplex Assay Introduction
11.12.4 Quanterix (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.12.5 Quanterix (US) Recent Development
11.13 Bio-Techne Corporation (US)
11.13.1 Bio-Techne Corporation (US) Company Detail
11.13.2 Bio-Techne Corporation (US) Business Overview
11.13.3 Bio-Techne Corporation (US) Nucleic Acid Multiplex Assay Introduction
11.13.4 Bio-Techne Corporation (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.13.5 Bio-Techne Corporation (US) Recent Development
11.14 Olink (Sweden)
11.14.1 Olink (Sweden) Company Detail
11.14.2 Olink (Sweden) Business Overview
11.14.3 Olink (Sweden) Nucleic Acid Multiplex Assay Introduction
11.14.4 Olink (Sweden) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.14.5 Olink (Sweden) Recent Development
11.15 DiaSorin S.p.A. (Italy)
11.15.1 DiaSorin S.p.A. (Italy) Company Detail
11.15.2 DiaSorin S.p.A. (Italy) Business Overview
11.15.3 DiaSorin S.p.A. (Italy) Nucleic Acid Multiplex Assay Introduction
11.15.4 DiaSorin S.p.A. (Italy) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.15.5 DiaSorin S.p.A. (Italy) Recent Development
11.16 Seegene (South Korea)
11.16.1 Seegene (South Korea) Company Detail
11.16.2 Seegene (South Korea) Business Overview
11.16.3 Seegene (South Korea) Nucleic Acid Multiplex Assay Introduction
11.16.4 Seegene (South Korea) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.16.5 Seegene (South Korea) Recent Development
11.17 Promega Corporation (US)
11.17.1 Promega Corporation (US) Company Detail
11.17.2 Promega Corporation (US) Business Overview
11.17.3 Promega Corporation (US) Nucleic Acid Multiplex Assay Introduction
11.17.4 Promega Corporation (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.17.5 Promega Corporation (US) Recent Development
11.18 Siemens Healthineers (Germany)
11.18.1 Siemens Healthineers (Germany) Company Detail
11.18.2 Siemens Healthineers (Germany) Business Overview
11.18.3 Siemens Healthineers (Germany) Nucleic Acid Multiplex Assay Introduction
11.18.4 Siemens Healthineers (Germany) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.18.5 Siemens Healthineers (Germany) Recent Development
11.19 PerkinElmer, Inc. (US)
11.19.1 PerkinElmer, Inc. (US) Company Detail
11.19.2 PerkinElmer, Inc. (US) Business Overview
11.19.3 PerkinElmer, Inc. (US) Nucleic Acid Multiplex Assay Introduction
11.19.4 PerkinElmer, Inc. (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.19.5 PerkinElmer, Inc. (US) Recent Development
11.20 Shimadzu Biotech (Japan)
11.20.1 Shimadzu Biotech (Japan) Company Detail
11.20.2 Shimadzu Biotech (Japan) Business Overview
11.20.3 Shimadzu Biotech (Japan) Nucleic Acid Multiplex Assay Introduction
11.20.4 Shimadzu Biotech (Japan) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.20.5 Shimadzu Biotech (Japan) Recent Development
11.21 Antigenix America, Inc. (US)
11.21.1 Antigenix America, Inc. (US) Company Detail
11.21.2 Antigenix America, Inc. (US) Business Overview
11.21.3 Antigenix America, Inc. (US) Nucleic Acid Multiplex Assay Introduction
11.21.4 Antigenix America, Inc. (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.21.5 Antigenix America, Inc. (US) Recent Development
11.22 Enzo Life Sciences, Inc. (US)
11.22.1 Enzo Life Sciences, Inc. (US) Company Detail
11.22.2 Enzo Life Sciences, Inc. (US) Business Overview
11.22.3 Enzo Life Sciences, Inc. (US) Nucleic Acid Multiplex Assay Introduction
11.22.4 Enzo Life Sciences, Inc. (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.22.5 Enzo Life Sciences, Inc. (US) Recent Development
11.23 Boster Biological Technology (US)
11.23.1 Boster Biological Technology (US) Company Detail
11.23.2 Boster Biological Technology (US) Business Overview
11.23.3 Boster Biological Technology (US) Nucleic Acid Multiplex Assay Introduction
11.23.4 Boster Biological Technology (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.23.5 Boster Biological Technology (US) Recent Development
11.24 AYOXXA Biosystems GmbH (Germany)
11.24.1 AYOXXA Biosystems GmbH (Germany) Company Detail
11.24.2 AYOXXA Biosystems GmbH (Germany) Business Overview
11.24.3 AYOXXA Biosystems GmbH (Germany) Nucleic Acid Multiplex Assay Introduction
11.24.4 AYOXXA Biosystems GmbH (Germany) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.24.5 AYOXXA Biosystems GmbH (Germany) Recent Development
11.25 Cayman Chemical Company (US)
11.25.1 Cayman Chemical Company (US) Company Detail
11.25.2 Cayman Chemical Company (US) Business Overview
11.25.3 Cayman Chemical Company (US) Nucleic Acid Multiplex Assay Introduction
11.25.4 Cayman Chemical Company (US) Revenue in Nucleic Acid Multiplex Assay Business (2018-2023)
11.25.5 Cayman Chemical Company (US) Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
